Overview

A Phase 1/2 Study in Patients With Advanced Cancers

Status:
Recruiting
Trial end date:
2027-04-01
Target enrollment:
Participant gender:
Summary
A first-in-human study using BIO-106 as a single agent and in combination with pembrolizumab in advanced cancers.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
BiOneCure Therapeutics Inc.
Treatments:
Pembrolizumab